A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.
about
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknownRegional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, CanadaIncrease in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003Predominance of herpes simplex virus type 1 from patients with genital herpes in Nova ScotiaThe seroepidemiology of herpes simplex virus type 1 and 2 in EuropeSeroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25-74 in 1992-93: a population-based studyMacrophages and cytokines in the early defence against herpes simplex virusOptimal management of genital herpes: current perspectivesHerpes simplex epithelial and stromal keratitis: an epidemiologic updateThe challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccineHerpes Genitalis: Diagnosis, Treatment and PreventionEvolutionary origins of human herpes simplex viruses 1 and 2Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein BNew concepts in understanding genital herpes.Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenAsymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.Ancient Recombination Events between Human Herpes Simplex VirusesImproving the care of patients with genital herpes.Recent advances: Sexually transmitted infections.Hormonal markers of susceptibility to sexually transmitted infections: are we taking them seriously?Decreasing seroprevalence of herpes simplex virus type 1 and type 2 in Germany leaves many people susceptible to genital infection: time to raise awareness and enhance controlCurrent status and prospects for development of an HSV vaccineRecent progress in herpes simplex virus immunobiology and vaccine researchSorting out the new HSV type specific antibody tests.Herpes simplex virus type 1 evades the effects of antibody and complement in vivoRole of herd immunity in determining the effect of vaccines against sexually transmitted disease.Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision.Differential reliance on autophagy for protection from HSV encephalitis between newborns and adultsChallenges in genital herpes simplex virus management.Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2.Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: a nested case-control study.Increased cell-mediated immune responses in patients with recurrent herpes simplex virus type 2 meningitisHLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgeniPhenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpesFirst episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology.Rising incidence and prevalence of herpes simplex type 2 infection in a cohort of 26 year old New ZealandersEstimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2.Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka.Patient satisfaction with care for genital herpes: insights from a global survey.
P2860
Q21296712-E44B417B-8A13-4A80-8228-A9E8B82DC0E2Q24550624-6036CBC5-1843-4F23-ACD0-85D250888743Q24654682-55088BE5-A3A9-4AF1-912E-AEC03F835196Q24670332-2DD690FF-9FE3-4767-BCCA-6F150F78C129Q24679583-99B35EBA-2372-4081-9C73-8F6BC7724407Q24791873-56E63C19-2AE3-4D27-9AF1-6AE2E4E8806BQ24815062-C1F93BBF-1767-4E04-9C56-DDFE6E2D1F3CQ26746041-49317988-C2E1-43D7-8D88-D05D2BFC96FFQ26853504-0DB30F35-B874-4878-A7E1-E89CE2F753CDQ27021292-B4D40690-5741-4D6F-97C4-A80799AFFA3DQ28067618-13A3F5A2-16E3-4D4A-8940-8D2A1B6FED20Q28654450-0EC4BE24-AE36-4450-9BD6-3BBFFE6CE413Q30847945-6B5DEA9D-9B32-4DDE-A191-D0D9660F085EQ33582145-F23CB110-4760-44D8-88B4-22D6B7C5B78AQ33663463-9AB5F49A-26E6-4A8C-A510-266EF392C177Q33755236-3D44A420-E74A-432D-8D2F-8AE12D814934Q33757196-1C1D0FAC-BAE7-46B5-9ED1-8AE8263B9DF9Q33801850-8A032614-5063-487B-8E47-DD93B92DAB5AQ33805422-2054A199-B3DE-4A59-8241-EF26F92FF5DBQ33806767-3AB1CDE4-6EBB-4D0D-BC87-FE1F1F554D44Q33882404-83A29C32-1C98-4B8D-8594-F88463DCC692Q33931016-54FD6FFB-E813-4F11-B9BE-3F6523F57A06Q33963713-4C740930-FBBD-418E-84D1-2BB36C028BB8Q34313806-A9672762-5FE3-4991-9436-9F9C1C41A148Q34345831-EA36B6FF-E11A-4CE5-89C2-6989F23721F9Q34380787-A52C5648-27B9-4EE2-90B8-AE639C60A47DQ34682912-916C2D11-498F-46B7-BB35-DE26C032C6B5Q34868359-CB7883B2-CB54-40DC-A880-819E03496168Q34876304-0202B11D-B482-4C6E-9529-7254D0FFE0ACQ34918258-0BD0CF4F-2499-4AD4-BB8F-7B284BA0A1AEQ34923432-23E8C25C-CB4D-47A2-98E5-9DC39FFC011BQ34998319-A9AA98BB-8CC6-4AF7-A0F0-79F94E7B4FC8Q35066312-176558EF-5B5D-4746-8814-54C06681E194Q35122383-C2228125-07D0-44AF-BB90-11683F947FB3Q35487893-1DF81277-EA76-4704-9D74-AED51D55B2EFQ35528603-A6618CC3-908A-4078-84D4-58A245A5D896Q35529535-18A56512-4444-479A-9DCE-FFC64D6831E6Q35530369-A1368895-7055-4B16-AE61-48BA45D96E61Q35530858-A7B27DD3-D5C5-4024-85D2-1CCFC4B54E70Q35531277-A9C65333-41E4-4501-96A7-5014FFAD0B21
P2860
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
A prospective study of new inf ...... hiron HSV Vaccine Study Group.
@en
A prospective study of new inf ...... hiron HSV Vaccine Study Group.
@nl
type
label
A prospective study of new inf ...... hiron HSV Vaccine Study Group.
@en
A prospective study of new inf ...... hiron HSV Vaccine Study Group.
@nl
prefLabel
A prospective study of new inf ...... hiron HSV Vaccine Study Group.
@en
A prospective study of new inf ...... hiron HSV Vaccine Study Group.
@nl
P2093
P1476
A prospective study of new inf ...... hiron HSV Vaccine Study Group.
@en
P2093
P304
P356
10.1056/NEJM199911043411904
P407
P577
1999-11-01T00:00:00Z